NCT03034135 - Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions

Recurrent Glioblastoma

Interventions

DRUG

Disulfiram/Copper

Disulfiram/copper gluconate is taken three times a day.

DRUG

Temozolomide (TMZ)

TMZ is given per standard of care

Trial Locations (8)

Lenox Hill Hospital, New York

Vanderbilt Ingram Cancer Center, Nashville

University of Cincinnati, Cincinnati

Beaumont Hospital, Royal Oak

Washington University School of Medicine, St Louis

Baylor University Medical Center, Dallas

John Theurer Cancer Center, Hackensack

Huntsman Cancer Institute, Salt Lake City